...
首页> 外文期刊>Canadian journal of anesthesia: Journal canadien d'anesthesie >Successful implementation of perioperative beta-blockade utilizing a multidisciplinary approach.
【24h】

Successful implementation of perioperative beta-blockade utilizing a multidisciplinary approach.

机译:使用多学科方法成功实施围手术期β受体阻滞剂。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: To describe how we implemented a protocol for perioperative beta-blockade in patients with or at risk of coronary artery disease (CAD) undergoing major non-cardiac surgery and to present our results. METHODS: After institutional approval, from May 1999 to April 2001, patients with surgical and medical indications (CAD as indicated by previous myocardial infarction, typical angina or atypical angina with a positive stress test or at least two risk factors for CAD: age 65 yr, hypertension, smoking, high cholesterol, diabetes mellitus) for perioperative beta-blockade were identified preoperatively by anesthesiology and referred to the General Internal Medicine Service (MED). MED initiated patients on outpatient beta-blockers. The intraoperative anesthetic management was left to the discretion of the anesthesiologist. In the postanesthesia care unit (PACU), patients received iv metoprolol according to hemodynamic criteria. Postoperatively, patients were followed by MED for adverse cardiac events. RESULTS: Sixty-nine patients received perioperative beta-blockade. Preoperatively, 60% were started on metoprolol, 39% on atenolol and 1% on propranolol. In PACU, 42%, 9% and 38% of patients were given iv metoprolol 0, 5 and 10 mg respectively. One patient was given glycopyrrolate in the PACU for bradycardia and none received vasoactive or inotropic agents. Three patients (4.3%) had postoperative cardiac events. CONCLUSIONS: With close collaboration between anesthesiologists, internists, PACU nurses and family physicians, a strategy for perioperative beta-blockade was implemented successfully in patients with cardiac risks. Beta-blockade was associated with few side effects and morbidities.
机译:目的:描述我们如何在进行大型非心脏手术的患有冠心病(CAD)或有冠心病(CAD)风险的患者中实施围手术期β-受体阻滞的方案,并介绍我们的结果。方法:经机构批准,从1999年5月至2001年4月,具有手术和医学适应症(CAD的患者为既往心肌梗死,典型的心绞痛或非典型心绞痛,并具有正压力测试或至少两个CAD危险因素:65岁)术前通过麻醉确定了高血压,吸烟,高血脂,糖尿病等围手术期的β-受体阻滞剂,并转诊至普通内科医学服务中心(MED)。 MED使患者开始使用门诊β受体阻滞剂。术中麻醉管理由麻醉医师自行决定。在麻醉后监护病房(PACU)中,患者根据血液动力学标准接受了静脉注射美托洛尔。术后,患者因不良心脏事件接受MED治疗。结果:69例患者接受了围手术期β受体阻滞剂治疗。术前,美托洛尔开始使用60%,阿替洛尔开始使用39%,普萘洛尔开始使用1%。在PACU中,分别有42%,9%和38%的患者接受美托洛尔静脉注射0、5和10 mg。一名患者在PACU中接受了格隆溴铵的心动过缓治疗,均未接受血管活性药物或正性肌力药。三名患者(4.3%)发生了术后心脏事件。结论:在麻醉医师,内科医师,PACU护士和家庭医生之间的密切合作下,成功地对患有心脏病的患者实施了围手术期β受体阻滞策略。 Beta阻滞剂几乎没有副作用和发病率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号